News
02-25-2011, 03:50 AM
Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.
More... (http://www.news-medical.net/news/20110225/The-Lancet-journal-publishes-XGEVA-Phase-3-study-results-against-prostate-cancer-bone-metastases.aspx)
More... (http://www.news-medical.net/news/20110225/The-Lancet-journal-publishes-XGEVA-Phase-3-study-results-against-prostate-cancer-bone-metastases.aspx)